Stem cell injection as well as preparation method and application thereof

By adding betalin and quinoa polypeptides to stem cell injection, combined with 0.9% sodium chloride injection and other ingredients, the problem of poor stem cell activity is solved, and the activity maintenance of stem cell and the inhibition of T lymphocyte proliferation is achieved. It is suitable for biomedicine Application in the field.

CN118902997APending Publication Date: 2024-11-08BEIJING HONGXIN TECHNOLOGY CO LTD

Patent Information

Application Number
CN202411109004.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

After preservation, the stem cell activity of existing stem cell injections is poor and cannot effectively exert immune function. The components need to be improved to improve the activity of stem cells.

Method used

Add bentool and quinoa polypeptides to the stem cell injection, and use 0.9% sodium chloride injection as the matrix, combining trehalose and vitamin C, and form stem cell injections to maintain stem cell activity through specific concentration ratios and preparation methods. Inhibit T lymphocyte proliferation.

Benefits of technology

It effectively maintains the activity of stem cells and significantly improves the ability to inhibit T lymphocyte proliferation, simplifies the preparation steps, and is suitable for applications in the field of biomedicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902997A_ABST
    Figure CN118902997A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a stem cell injection as well as a preparation method and application thereof. The stem cell injection comprises a 0.9% sodium chloride injection and the following components added in the 0.9% sodium chloride injection: trehalose, vitamin C, dextran-40, betulin, quinoa polypeptide and stem cells. The concentrations of the components in the injection are as follows: 1-5 mg / mL of trehalose, 5-10 [mu] g / mL of vitamin C, 0.5-3 mg / mL of dextran-40, 0.5-1 [mu] g / mL of betulin, 4-8 [mu] g / mL of quinoa polypeptide and 1-5 * 10 < 7 > stem cells / mL. The activity detection of the stem cells in the stored stem cell injection shows that the activity of the stem cells can be effectively maintained through the synergistic effect of the betulin and the quinoa polypeptide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a stem cell injection solution and a preparation method and application thereof. Background Art

[0002] Mesenchymal stem cells, also known as mesenchymal stromal cells, are a type of multipotent stem cells. Mesenchymal stem cells do not have tissue specificity and exist in almost all tissues, such as bone marrow, fat, umbilical cord, kidney, liver, lung, etc. Mesenchymal stem cells can also differentiate into bone, neurons, cardiomyocytes and other tissues. In addition, mesenchymal stem cells also have strong multidirectional differentiation ability and immunosuppressive ability, and can regulate immune responses by secreting cytokines and immunomodulatory substances. Therefore, they have attracted much attention in the fields of tissue regeneration and tumor immunity.

[0003] T lymphocytes are multipotent stem cells derived from the bone marrow. After differentiation and maturation in the thymus, they are distributed to immune organs and tissues throughout the body through lymphatic and blood circulation to exert immune functions. T lymphocytes can directly kill target cells, assist or inhibit B cells in producing antibodies, respond to specific antigens and mitogens, and produce cytokines. With the deepening of research on mesenchymal stem cells, scholars have found that mesenchymal stem cells can interact with adaptive immune cells, inhibit B cell activation, inhibit T cell proliferation and activation, induce TH1 to TH2 transformation, inhibit CD8+T cell activity, and protect regulatory T cells.

[0004] Based on the above theoretical foundation, stem cell injections have gradually entered the field of biomedical technology. Existing stem cell injections have the technical problem that stem cells have poor activity after preservation, which makes it impossible for stem cells to play an immune role well. In view of this, it is necessary to improve the ingredients of stem cell injections to improve the activity of stem cells. Summary of the invention

[0005] The first object of the present invention is to provide a stem cell injection solution that can inhibit the proliferation of T lymphocytes.

[0006] The second purpose of the present invention is to provide a method for preparing a stem cell injection solution, which is simple, easy to operate and practice.

[0007] The third purpose of the present invention is to provide an application of stem cell injection, which has broad application prospects.

[0008] In order to achieve the above object, the technical solution adopted by the present invention is:

[0009] A stem cell injection, comprising 0.9% sodium chloride injection and the following components added to the 0.9% sodium chloride injection: trehalose, vitamin C, dextran-40, betulin, quinoa polypeptide, and stem cells; the concentrations of the components in the injection are: trehalose 1-5 mg / mL, vitamin C 5-10 μg / mL, dextran-40 0.5-3 mg / mL, betulin 0.5-1 μg / mL, quinoa polypeptide 4-8 μg / mL, stem cells 1-5×10 7 Pieces / mL.

[0010] Furthermore, the amino acid sequence of the quinoa polypeptide is MMFPH.

[0011] Furthermore, the stem cells are P3-P5 generation stem cells that are cultured in succession.

[0012] Furthermore, the stem cells are selected from adipose mesenchymal stem cells, bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells, and amniotic membrane mesenchymal stem cells.

[0013] The preparation method of the above stem cell injection solution comprises the following steps:

[0014] (1) taking 0.9% sodium chloride injection, trehalose, vitamin C, dextran-40, betulin, and quinoa polypeptide according to the above concentrations, mixing them evenly, filtering and sterilizing to obtain a mixed solution, and precooling at 4-6° C. for later use;

[0015] (2) Add the stem cells to the mixed solution of step (1) and resuspend them to obtain a stem cell injection solution.

[0016] Furthermore, the pore size of the filter used for the filtration sterilization in step (1) is 0.22 μm.

[0017] The application of the above stem cell injection is used in the preparation of products for inhibiting T lymphocyte proliferation.

[0018] Compared with the prior art, the beneficial effects of the present invention are mainly:

[0019] (1) Improve the composition of injection solution

[0020] The present invention adds ingredients such as betulin and quinoa polypeptide to the stem cell injection. The activity detection of stem cells in the stem cell injection after preservation found that the synergistic effect of betulin and quinoa polypeptide can effectively maintain the activity of stem cells.

[0021] (2) Simplify the preparation steps

[0022] The present invention simplifies the preparation steps of stem cell injection, making it easier to operate and more conducive to actual production. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 These are morphological diagrams of bone marrow mesenchymal stem cells of generations P3-P5, wherein A is a morphological diagram of bone marrow mesenchymal stem cells of generation P3, B is a morphological diagram of bone marrow mesenchymal stem cells of generation P4, and C is a morphological diagram of bone marrow mesenchymal stem cells of generation P5;

[0024] Figure 2 The morphological diagrams of adipose-derived mesenchymal stem cells of generations P3-P5, wherein A is the morphological diagram of adipose-derived mesenchymal stem cells of generation P3, B is the morphological diagram of adipose-derived mesenchymal stem cells of generation P4, and C is the morphological diagram of adipose-derived mesenchymal stem cells of generation P5;

[0025] Figure 3 It is the result of the inhibition rate of bone marrow mesenchymal stem cell injection on T lymphocyte proliferation;

[0026] Figure 4 It is the result of the inhibition rate of adipose-derived mesenchymal stem cell injection on T lymphocyte proliferation. DETAILED DESCRIPTION

[0027] The technical scheme of the present invention is further described below in conjunction with specific embodiments. However, it should be understood by those skilled in the art that the following examples are only used to illustrate the present invention and should not be regarded as limiting the present invention. The specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used, unless otherwise specified, are conventional products obtained through commercial channels.

[0028] Example 1

[0029] This embodiment provides a stem cell injection, which is composed of 0.9% sodium chloride injection and the following ingredients added to the 0.9% sodium chloride injection: trehalose, vitamin C, dextran-40, betulin, quinoa polypeptide (amino acid sequence is MMFPH), and P3 generation bone marrow mesenchymal stem cells. Among them, the preparation process of quinoa polypeptide (amino acid sequence is MMFPH) refers to Zhou Haochun et al. "Isolation and Mechanism Research of Quinoa α-Amylase Inhibitory Active Peptide". The concentrations of the above ingredients in 0.9% sodium chloride injection are shown in Table 1.

[0030] Table 1

[0031] Element concentration Trehalose 2mg / mL Vitamin C 7 μg / mL Dextran-40 2.4mg / mL Betulin 0.6 μg / mL Quinoa peptides 5 μg / mL P3 bone marrow mesenchymal stem cells <![CDATA[3×10 7 pcs / mL]]>

[0032] The preparation method of the above stem cell injection solution, the specific preparation process is as follows:

[0033] (1) Weigh each component according to the concentration of each component above, mix 0.9% sodium chloride injection, trehalose, vitamin C, dextran-40, betulin, and quinoa polypeptide evenly, filter and sterilize using a filter with a pore size of 0.22 μm to obtain a mixed solution, precool at 4° C. for 30 minutes, and set aside;

[0034] (2) Add the stem cells to the mixed solution of step (1) and resuspend them to prepare a stem cell injection solution, which is divided into 5 mL storage bags and stored in a 4°C refrigerator.

[0035] Example 2

[0036] This embodiment provides a stem cell injection, which is composed of 0.9% sodium chloride injection and the following ingredients added to the 0.9% sodium chloride injection: trehalose, vitamin C, dextran-40, betulin, quinoa polypeptide (amino acid sequence is MMFPH), and P4 generation bone marrow mesenchymal stem cells. Among them, the preparation process of quinoa polypeptide (amino acid sequence is MMFPH) refers to Zhou Haochun et al. "Isolation and Mechanism of Quinoa α-Amylase Inhibitory Active Peptide". The concentrations of the above ingredients in 0.9% sodium chloride injection are shown in Table 2.

[0037] Table 2

[0038] Element concentration Trehalose 1mg / mL Vitamin C 5 μg / mL Dextran-40 0.5mg / mL Betulin 0.5 μg / mL Quinoa peptides 4 μg / mL P4 bone marrow mesenchymal stem cells <![CDATA[1×10 7 pcs / mL]]>

[0039] The preparation method of the above stem cell injection solution, the specific preparation process is as follows:

[0040] (1) Weigh each component according to the concentration of each component above, mix 0.9% sodium chloride injection, trehalose, vitamin C, dextran-40, betulin, and quinoa polypeptide evenly, filter and sterilize using a filter with a pore size of 0.22 μm to obtain a mixed solution, precool at 5° C. for 30 minutes, and set aside;

[0041] (2) Add stem cells to the mixed solution of step (1) and resuspend to prepare stem cell injection solution, which is divided into 5 mL storage bags and stored at 4°C.

[0042] Example 3

[0043] This embodiment provides a stem cell injection, which is composed of 0.9% sodium chloride injection and the following ingredients added to the 0.9% sodium chloride injection: trehalose, vitamin C, dextran-40, betulin, quinoa polypeptide (amino acid sequence is MMFPH), and P5 generation bone marrow mesenchymal stem cells. Among them, the preparation process of quinoa polypeptide (amino acid sequence is MMFPH) refers to Zhou Haochun et al. "Isolation and Mechanism of Quinoa α-Amylase Inhibitory Active Peptide". The concentrations of the above ingredients in 0.9% sodium chloride injection are shown in Table 3.

[0044] Table 3

[0045] Element concentration Trehalose 5mg / mL Vitamin C 10 μg / mL Dextran-40 3mg / mL Betulin 1 μg / mL Quinoa peptides 8 μg / mL P5 bone marrow mesenchymal stem cells <![CDATA[5×10 7 pcs / mL]]>

[0046] The preparation method of the above stem cell injection solution, the specific preparation process is as follows:

[0047] (1) Weigh each component according to the concentration of each component above, mix 0.9% sodium chloride injection, trehalose, vitamin C, dextran-40, betulin, and quinoa polypeptide evenly, filter and sterilize using a filter with a pore size of 0.22 μm to obtain a mixed solution, precool at 6° C. for 30 minutes, and set aside;

[0048] (2) Add the stem cells to the mixed solution of step (1) and resuspend them to prepare a stem cell injection solution, which is divided into 5 mL storage bags and stored in a 4°C refrigerator.

[0049] The bone marrow mesenchymal stem cells of Examples 1-3 were replaced with adipose mesenchymal stem cells to form Examples 4-6.

[0050] Comparative Example 1

[0051] The difference between this comparative example and Example 1 is that betulin is lacking in the injection.

[0052] Comparative Example 2

[0053] The difference between this comparative example and Example 1 is that the injection lacks quinoa polypeptide.

[0054] Comparative Example 3

[0055] The difference between this comparative example and Example 1 is that the injection lacks betulin and the concentration of quinoa polypeptide is 5.6 μg / mL.

[0056] Comparative Example 4

[0057] The difference between this comparative example and Example 1 is that the injection lacks quinoa polypeptide and the concentration of betulin is 5.6 μg / mL.

[0058] Comparative Example 5

[0059] The difference between this comparative example and Example 1 is that the injection lacks betulin and quinoa polypeptide.

[0060] The bone marrow mesenchymal stem cells of Comparative Examples 1-5 were replaced with adipose mesenchymal stem cells to form Comparative Examples 6-10.

[0061] Experimental Example 1

[0062] The storage bags of Examples 1-6 and Comparative Examples 1-10 after being stored for 24h, 48h, and 72h were immersed in a 37°C water bath until the injection solution in the storage bag was completely melted, and the cell suspension was mixed by gently blowing 12 times with a pipette, and 15μL of the cell suspension and 15μL of AO / PI dye solution were mixed by blowing with a pipette, and 20μL of the mixed solution was placed in a counting plate, and counted using an automatic fluorescence analyzer, and the cell viability of each group after recovery was statistically analyzed (the average value of 3 parallel experiments), and the results are shown in Table 4-5. Note: The viability of bone marrow mesenchymal stem cells in the injection before storage was 99.17%, and the viability of adipose mesenchymal stem cells was 98.64%.

[0063] Table 4 Viability of bone marrow mesenchymal stem cells

[0064] Group / survival rate (%) 24h 48h 72h Example 1 98.75 96.04 91.82 Example 2 98.42 95.76 91.43 Example 3 97.96 94.19 90.30 Comparative Example 1 85.24 82.91 81.07 Comparative Example 2 69.51 64.26 63.81 Comparative Example 3 85.87 83.52 81.96 Comparative Example 4 75.10 72.04 68.45 Comparative Example 5 61.08 56.27 51.30

[0065] Table 5 Viability of adipose-derived mesenchymal stem cells

[0066]

[0067]

[0068] From Table 4-5, it can be seen that the cell viability of the stem cell injection solution of Examples 1-6 after preservation is above 89.97%. Therefore, it can be seen that the stem cell injection solution of Examples 1-6 can maintain the viability of stem cells.

[0069] Compared with the stem cell injection of Example 1-6, the stem cell injection of Comparative Example 1-10 changed the dosage of quinoa polypeptide and betulin, so that the viability of stem cells was significantly reduced. It can be seen that the synergistic effect of quinoa polypeptide and betulin can effectively maintain the viability of stem cells.

[0070] Experimental Example 2

[0071] (1) After 3 days of storage, the storage bags of Examples 1-6 and Comparative Examples 1-10 were immersed in a 37°C water bath until the injection solution in the storage bag melted. The thawed stem cell injection solution was transferred to a 50 mL centrifuge tube, an equal volume of α-MEM medium was added, and the mixture was centrifuged at 1200 rpm for 8 min. The supernatant was discarded, and the cells were resuspended in α-MEM medium to a cell concentration of 1×10 4 / mL, and the resuscitated stem cells of Examples 1-6 and Comparative Examples 1-10 were obtained for later use.

[0072] (2) Collect venous peripheral blood using an anticoagulant tube containing heparin, and then transfer the blood to a centrifuge tube. Dilute the peripheral blood with physiological saline to obtain a peripheral blood dilution solution. Add lymphocyte separation solution to another new centrifuge tube, and then carefully add the peripheral blood dilution solution to the centrifuge tube. Centrifuge the tube at 1500 g for 15 min to separate the liquid in the centrifuge tube. Carefully aspirate the white film layer cells, wash them, and inoculate them into α-MEM culture medium (8% FBS, 1200 IU / mL IL-2, 700 IU / mL IL-15, 20 μg / L CD3 monoclonal antibody). Culture them in a cell culture incubator at 37°C and 5% CO2 for 14 days to obtain T lymphocytes for later use.

[0073] (3) Experimental groups

[0074] The culture medium was α-MEM complete medium containing 8% FBS and 1% penicillin-streptomycin-antibody.

[0075] Group 1 is a stem cell group: the stem cells of Examples 1-6 and Comparative Examples 1-10 were seeded into a 12-well plate and cultured separately;

[0076] Group 2 was a T lymphocyte unstained control group: T lymphocytes were inoculated into a 12-well plate and cultured alone;

[0077] Group 3 was the T lymphocyte staining control group: T lymphocytes were stained with CFDA SE and then inoculated into 12-well plates and cultured alone;

[0078] Group 4 was the T lymphocyte activation staining control group: T lymphocytes were stained with CFDA SE, activated with PHA at a final concentration of 1 mg / mL, and then inoculated into a 12-well plate and cultured alone;

[0079] Group 5 was the T lymphocyte activation staining and stem cell co-culture group: T lymphocytes were stained with CFDA SE, activated with PHA at a final concentration of 1 mg / mL, and then inoculated into a 12-well plate at a ratio of 1:4 between stem cells and T lymphocytes for co-culture.

[0080] (4) After 4 days of culture, carefully aspirate the supernatant from each group of 12-well plates and transfer it to a centrifuge tube. After centrifugation, discard the supernatant, add 1 mL of PBS to the centrifuge tube, centrifuge again, discard the supernatant, and test on a microscope. The calculation formula for the inhibition rate of stem cells on T lymphocyte proliferation is as follows:

[0081] Inhibition rate = (proportion of CFDA SE progeny cells of single T lymphocytes - proportion of CFDA SE progeny cells of co-culture of T lymphocytes and stem cells) / proportion of CFDA SE progeny cells of single T lymphocytes × 100%. The results are as follows Figure 3-4 shown.

[0082] Figure 3 It is the result of the inhibition rate of bone marrow mesenchymal stem cell injection on T lymphocyte proliferation. Figure 4 This is the result of the inhibition rate of adipose-derived mesenchymal stem cell injection on T lymphocyte proliferation. Figure 3-4 It can be seen that the stem cell injection of Example 1-6 has a stronger ability to inhibit T lymphocyte proliferation than that of Comparative Examples 1-10. The above results show that the injection of the present invention can be used to prepare a product that inhibits T lymphocyte proliferation.

[0083] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them. The basic principles and main features of the present invention have been described above with specific implementation schemes. On the basis of the present invention, some modifications or replacements may be made thereto, but these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of protection claimed by the present invention.

Claims

1. A stem cell injection, characterized in that: The injection comprises 0.9% sodium chloride injection and the following components added to the 0.9% sodium chloride injection: trehalose, vitamin C, dextran-40, betulin, quinoa polypeptide, and stem cells; the concentrations of the components in the injection are: trehalose 1-5 mg / mL, vitamin C 5-10 μg / mL, dextran-40 0.5-3 mg / mL, betulin 0.5-1 μg / mL, quinoa polypeptide 4-8 μg / mL, stem cells 1-5×10 7 Pieces / mL.

2. The stem cell injection according to claim 1, characterized in that: The amino acid sequence of the quinoa polypeptide is MMFPH.

3. The stem cell injection according to claim 1, characterized in that: The stem cells are P3-P5 generation stem cells that are cultured through successive generations.

4. The stem cell injection according to claim 3, characterized in that: The stem cells are selected from adipose mesenchymal stem cells, bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells, and amniotic membrane mesenchymal stem cells.

5. The method for preparing the stem cell injection according to any one of claims 1 to 4, characterized in that: The following steps are involved: (1) According to claim 1, 0.9% sodium chloride injection, trehalose, vitamin C, dextran-40, betulin, and quinoa polypeptide are mixed evenly and filtered to sterilize to obtain a mixed solution, which is pre-cooled at 4-6°C for later use; (2) Add the stem cells to the mixed solution of step (1) and resuspend them to obtain a stem cell injection solution.

6. The method for preparing the stem cell injection solution according to claim 5, characterized in that: The pore size of the filter used for filtration sterilization in step (1) is 0.22 μm.

7. The use of the stem cell injection according to any one of claims 1 to 6, characterized in that: Application in the preparation of products for inhibiting T lymphocyte proliferation.

Citation Information

Patent Citations

  • Human placenta mesenchymal stem cell suspension protection agent

    CN108184818A

  • Human mesenchymal stem cell injection and application thereof

    CN116077448A

  • Betulin derivative exhibiting cell membrane stabilization effect and production method thereof

    JP2017014174A

Cited By

  • Amniotic mesenchymal stem cell injection and large-scale construction method thereof

    CN120305203A

  • Amniotic membrane mesenchymal stem cell injection and large-scale construction method thereof

    CN120305203B